BackSarepta Therapeutics Overview
Sarepta Therapeutics Inc

Sarepta Therapeutics Target Price

Analysts' average 12-month price target for Sarepta Therapeutics is $23.

Get informed when a big investor buys or sells

+ Follow

Share Price

$20.92

Average Target Price

$22.758.7% upside

4 analysts in the last 4 months

High: $27 | Low: $19

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-27Morgan Stanley$2519.5% upsideOpen
2026-07-09Piper Sandler$204.4% downsideOpen
2026-07-08Wolfe Research$2729.1% upsideOpen
2026-05-15Evercore ISI$199.2% downsideOpen
2026-03-26Deutsche Bank$1433.1% downsideOpen
2026-03-26Wedbush$3567.3% upsideOpen
2026-03-12Mizuho SecuritiesUy Ear$3148.2% upsideOpen
2026-03-03Loop Capital MarketsIlya Zubkov$2519.5% upsideOpen
2026-03-03JefferiesAndrew Tsai$3043.4% upsideOpen
2026-01-27Robert W. Baird$225.2% upsideOpen
2025-12-09Wedbush$3253% upsideOpen
2025-11-25Bernstein$204.4% downsideOpen
2025-11-05Barclays$204.4% downsideOpen
2025-11-05Mizuho SecuritiesUy Ear$2624.3% upsideOpen
2025-11-04Robert W. BairdBrian Skorney$1528.3% downsideOpen
2025-10-30Piper SandlerBiren Amin$1623.5% downsideOpen
2025-09-09Leerink PartnersJoseph Schwartz$1528.3% downsideOpen
2025-08-21Barclays$225.2% upsideOpen
2025-08-15Deutsche BankDavid Hoang$1242.6% downsideOpen
2025-07-22BarclaysGena Wang$1814% downsideOpen
2025-07-21BMO CapitalKostas Biliouris$50139% upsideOpen
2025-07-19Leerink PartnersJoseph Schwartz$1052.2% downsideOpen
2025-06-25H.C. Wainwright$1052.2% downsideOpen
2025-06-17Wells FargoYanan Zhu$75258.5% upsideOpen
2025-06-16Cantor FitzgeraldKristen Kluska$204.4% downsideOpen
2025-06-15BMO CapitalKostas Biliouris$70234.6% upsideOpen
2025-04-21Piper Sandler$110425.8% upsideOpen
2024-11-27Piper SandlerBiren Amin$182770% upsideOpen
2024-11-27NeedhamGil Blum$202865.6% upsideOpen
2024-11-07Robert W. BairdBrian Skorney$193822.6% upsideOpen
2024-11-07Cantor FitzgeraldKristen Kluska$167698.3% upsideOpen
2024-10-21JefferiesAndrew Tsai$165688.7% upsideOpen
2024-08-08Evercore ISIGavin Clark-Gartner$179755.6% upsideOpen
2024-08-08Piper SandlerBiren Amin$200856% upsideOpen
2024-08-08BarclaysGena Wang$203870.4% upsideOpen
2024-08-08RBC CapitalBrian Abrahams$181765.2% upsideOpen
2024-07-29RBC CapitalBrian Abrahams$182770% upsideOpen
2024-06-27BMO CapitalKostas Biliouris$200856% upsideOpen
2024-06-26Piper SandlerBiren Amin$205879.9% upsideOpen
2024-06-24Evercore ISIGavin Clark-Gartner$185784.3% upsideOpen
2024-06-24Mizuho SecuritiesUy Ear$200856% upsideOpen
2024-06-21Robert W. BairdBrian Skorney$200856% upsideOpen
2024-06-13Robert W. BairdBrian Skorney$170712.6% upsideOpen
2024-06-13Piper SandlerBiren Amin$157650.5% upsideOpen
2024-06-13BarclaysGena Wang$185784.3% upsideOpen
2024-06-07BMO CapitalKostas Biliouris$170712.6% upsideOpen
2024-05-28RBC CapitalBrian Abrahams$142578.8% upsideOpen
2024-05-20RBC CapitalBrian Abrahams$157650.5% upsideOpen
2024-05-17Mizuho SecuritiesUy Ear$179755.6% upsideOpen
2024-05-14OppenheimerHartaj Singh$180760.4% upsideOpen

Sarepta Therapeutics (SRPT) FAQ

Sarepta Therapeutics's target price stands at $23. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $23 for SRPT implies 8.7% upside versus today's price ($20.92). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Sarepta Therapeutics's target price evolved across reporting periods, while the comparison chart places SRPT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Sarepta Therapeutics's reading of $23 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.